Current Major Cancer Targets for Nanoparticle Systems
How nanoparticles can be used as drug delivery systems and imaging devices to increase the efficacy per dose of therapeutic or imaging contrast agents; how nanoparticles will be further developed to improve their functionality in cancer treatment and imaging? How reacts the immune system of the organism after introducing nanoparticles with the aim to defeat tumors? Here the aim was to discuss the right and wrong applications of NP and to answer to some of these questions. In the mean time there will appeare much more investigations because of the important application of the NP not only as drug delivery systems, but as diagnostics as well.
Keywords: Alzheimer's; DNA-cisplatin; DNA-cisplatin-gold; Ferroelectric materials; Nano-particles; Parkinson's; alveolar epithelial cells; alveolar macrophages; antifungal effects; arrhythmia; arteriosclerosis; autoimmune diseases; biological toxicity; cancer imaging; cancer treatment; cardiovascular diseases; cellular redox balance; chemotherapeutic agent; chromium; chronic pulmonary inflammation; cisplatin; cobalt-chromium; cytometry analysis; dimercapto-succinic acid; diseases; electromagnetic properties; erythematosus; esophageal; gastrointestinal tract-even; glucose-release test; hemagglutinin; lymph nodes; magnetic nanoparticles; mesothelioma; micronucleus; nano-Ag; nanotechnology; palladium complexes; pheochromocytoma; phospholipid bilayers; plasmid-cisplatin; platinum; pulmonary effects; pulmonary fibrosis; rheumatoid; scleroderma; solar spectrum; sulfides, nitrides; titanium dioxide; tobacco smoke; transmission electron microscopy
Document Type: Research Article
Publication date: 01 February 2011
- Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites